| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Clinical Chemistry, Vol 41, 444-447, Copyright © 1995 by American Association for Clinical Chemistry
JF Lassen, I Brandslund and S Antonsen
Department of Clinical Chemistry, Vejle County Hospital, Denmark.
To determine when a change in serial measurements of prothrombin time in patients receiving oral anticoagulant therapy (ACT) is a statistically significant biological change necessitating dose adjustment, one must know the size of the "critical difference" in statistical terms (i.e., probabilities). In a cohort of 32 ACT patients at pharmacological steady-state, we studied the within-subject total variation of prothrombin time, expressed as International Normalized Ratio (INR), over 6 months. The total within-subject variation (CV) of INR was 10.1%. The corresponding critical differences required for significance of change in serial INR results was 0.7 at a therapeutic target of 2.5 INR and 1.0 at a therapeutic target of 3.5 INR. The data presented allow generation of objective criteria for monitoring ACT patients and deciding dose adjustments. We recommend that estimations of critical differences for significant change of INR in ACT patients should be based on results obtained in the specific clinic investigated to mirror the routine total variation of INR measurements they obtain.
The following articles in journals at HighWire Press have cited this article:
|
|
 |
|
  A.-H. Kristoffersen, G. Thue, and S. Sandberg Postanalytical External Quality Assessment of Warfarin Monitoring in Primary Healthcare Clin. Chem., October 1, 2006; 52(10): 1871 - 1878. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Horsti, H. Uppa, and J. A Vilpo Poor Agreement among Prothrombin Time International Normalized Ratio Methods: Comparison of Seven Commercial Reagents Clin. Chem., March 1, 2005; 51(3): 553 - 560. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Vincze and A. Parthan The Value of Home Monitoring Kits in Diabetes, Hypertension, Asthma, and Oral Anticoagulation Therapy Journal of Pharmacy Practice, June 1, 2004; 17(3): 182 - 196. [Abstract] [PDF]
|
|
|
|
 |
|
 E. Murray and M Greaves INRs and point of care testing BMJ, July 3, 2003; 327(7405): 5 - 6. [Full Text] [PDF]
|
|
|
|
 |
|
 B. G. Macik, J. H. Rand, and B. A. Konkle Thrombophilia: What's a Practitioner to Do? Hematology, January 1, 2001; 2001(1): 322 - 338. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Kjeldsen, J. F. Lassen, P. H. Petersen, and I. Brandslund Biological variation of International Normalized Ratio for prothrombin times, and consequences in monitoring oral anticoagulant therapy: computer simulation of serial measurements with goal-setting for analytical quality Clin. Chem., November 1, 1997; 43(11): 2175 - 2182. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Stahl, I. Brandslund, S. Iversen, and J. A. Filtenborg Quality assessment of blood glucose testing in general practitioners' offices improves quality Clin. Chem., October 1, 1997; 43(10): 1926 - 1931. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
